Regenerative medicine continues to evolve, and one of the most exciting areas of interest today is extracellular vesicle (EV)-rich preparations, often referred to as exosome-related technologies.
While many exosome-based products on the market rely on externally sourced biological materials, autologous approaches are gaining attention because they use the patient's own blood as the starting material.
For healthcare professionals, this opens the door to a more personalised regenerative strategy.
The word autologous means that the biological material comes from the same patient who will receive the treatment.
In the context of regenerative medicine, this means the preparation is produced from the patient’s own blood rather than donor-derived or externally manufactured biological sources.
Uses the patient’s own biological material
Avoids reliance on donor-derived sources
Supports a more personalised treatment concept
Offers a point-of-care workflow for clinics
These features are among the reasons why autologous extracellular vesicle-rich systems are attracting increasing interest in aesthetic and regenerative medicine.
| Feature | Autologous Approach | Externally Sourced Approach |
|---|---|---|
| Biological source | Patient’s own blood | Donor-derived or manufactured source |
| Workflow | Prepared close to the point of care | Produced externally |
| Personalisation | Patient-specific | Standardised external product |
| Supply dependency | Lower | Higher |
| Key consideration | Protocol quality and consistency | Source, manufacturing and quality control |
Suggested Visual 1:
A clean comparison infographic titled “Autologous vs Externally Sourced Exosome Approaches” with icons for blood sample, clinic workflow, donor source, and product handling.
Not all extracellular vesicle-related systems are the same.
What matters is not just the word exosome, but also:
the biological source,
the preparation protocol,
the particle characterisation,
and the reproducibility of the workflow.
For clinics exploring regenerative technologies, a structured and well-defined preparation process is essential.
One of the most innovative solutions in this field is D-MED EXOMAS EXO, available through Krios Biotech in the Netherlands and Belgium.
D-MED EXOMAS EXO is an autologous extracellular vesicle-rich plasma preparation system designed to process the patient’s own blood through a dedicated protocol.
The system combines:
Advanced PRX Tube Technology
Cellitium Blade Technology
A structured preparation workflow designed for extracellular vesicle-rich plasma processing
This makes it a highly interesting option for professionals who want to explore an autologous regenerative approach in a practical clinical setting.
Suggested Visual 2:
Product image of the D-MED EXOMAS EXO Kit placed here with a caption such as:
“D-MED EXOMAS EXO: an autologous extracellular vesicle-rich plasma preparation system.”
According to manufacturer-reported analytical data, the EXOMAS protocol demonstrated:
1.56 × 10¹² particles/mL
Average particle size: 128.7 nm
Analysis method: Nanoparticle Tracking Analysis (NTA)
This analytical profile highlights the ability of the system to generate a high measured particle concentration under reported testing conditions.
| Parameter | Reported Result |
|---|---|
| Particle concentration | 1.56 × 10¹² particles/mL |
| Average particle size | 128.7 nm |
| Analysis method | NTA |
| Sample origin | Autologous blood-derived preparation |
Suggested Visual 3:
A simple bar or highlight chart showing:
Particle Concentration → 1.56 × 10¹² particles/mL
Average Particle Size → 128.7 nm
Autologous extracellular vesicle-rich systems may be of particular interest to clinics exploring:
aesthetic skin rejuvenation concepts,
regenerative treatment workflows,
hair and scalp-related applications,
and patient-specific biological treatment strategies.
For professionals already working with PRP or other regenerative technologies, EXOMAS EXO offers an opportunity to evaluate a more advanced autologous concept.
Krios Biotech B.V. is the distributor of D-MED regenerative medicine technologies in the Netherlands and Belgium.
We support healthcare professionals with:
product information,
technical documentation,
scientific background,
and personalised guidance.
Our portfolio includes:
D-MED PRP systems
D-MED EXOMAS EXO
NUMATRIX Micro-Graft
CELLANOVA Elite SVF
LIPANOVA
BMAC systems
Suggested Visual 4:
A small product portfolio strip or icon row showing PRP, EXOMAS, NUMATRIX, CELLANOVA, and LIPANOVA.
Autologous extracellular vesicle-rich plasma preparation is an exciting and developing area of regenerative medicine.
If you are interested in learning more about D-MED EXOMAS EXO, Krios Biotech would be pleased to support you with further product information and technical documentation.
Regenerative medicine continues to evolve, and one of the most exciting areas of interest today is extracellular vesicle (EV)-rich preparations, often referred to as exosome-related technologies.
While many exosome-based products on the market rely on externally sourced biological materials, autologous approaches are gaining attention because they use the patient's own blood as the starting material.
For healthcare professionals, this opens the door to a more personalised regenerative strategy.
The word autologous means that the biological material comes from the same patient who will receive the treatment.
In the context of regenerative medicine, this means the preparation is produced from the patient’s own blood rather than donor-derived or externally manufactured biological sources.
Uses the patient’s own biological material
Avoids reliance on donor-derived sources
Supports a more personalised treatment concept
Offers a point-of-care workflow for clinics
These features are among the reasons why autologous extracellular vesicle-rich systems are attracting increasing interest in aesthetic and regenerative medicine.
| Feature | Autologous Approach | Externally Sourced Approach |
|---|---|---|
| Biological source | Patient’s own blood | Donor-derived or manufactured source |
| Workflow | Prepared close to the point of care | Produced externally |
| Personalisation | Patient-specific | Standardised external product |
| Supply dependency | Lower | Higher |
| Key consideration | Protocol quality and consistency | Source, manufacturing and quality control |
Suggested Visual 1:
A clean comparison infographic titled “Autologous vs Externally Sourced Exosome Approaches” with icons for blood sample, clinic workflow, donor source, and product handling.
Not all extracellular vesicle-related systems are the same.
What matters is not just the word exosome, but also:
the biological source,
the preparation protocol,
the particle characterisation,
and the reproducibility of the workflow.
For clinics exploring regenerative technologies, a structured and well-defined preparation process is essential.
One of the most innovative solutions in this field is D-MED EXOMAS EXO, available through Krios Biotech in the Netherlands and Belgium.
D-MED EXOMAS EXO is an autologous extracellular vesicle-rich plasma preparation system designed to process the patient’s own blood through a dedicated protocol.
The system combines:
Advanced PRX Tube Technology
Cellitium Blade Technology
A structured preparation workflow designed for extracellular vesicle-rich plasma processing
This makes it a highly interesting option for professionals who want to explore an autologous regenerative approach in a practical clinical setting.
Suggested Visual 2:
Product image of the D-MED EXOMAS EXO Kit placed here with a caption such as:
“D-MED EXOMAS EXO: an autologous extracellular vesicle-rich plasma preparation system.”
According to manufacturer-reported analytical data, the EXOMAS protocol demonstrated:
1.56 × 10¹² particles/mL
Average particle size: 128.7 nm
Analysis method: Nanoparticle Tracking Analysis (NTA)
This analytical profile highlights the ability of the system to generate a high measured particle concentration under reported testing conditions.
| Parameter | Reported Result |
|---|---|
| Particle concentration | 1.56 × 10¹² particles/mL |
| Average particle size | 128.7 nm |
| Analysis method | NTA |
| Sample origin | Autologous blood-derived preparation |
Suggested Visual 3:
A simple bar or highlight chart showing:
Particle Concentration → 1.56 × 10¹² particles/mL
Average Particle Size → 128.7 nm
Autologous extracellular vesicle-rich systems may be of particular interest to clinics exploring:
aesthetic skin rejuvenation concepts,
regenerative treatment workflows,
hair and scalp-related applications,
and patient-specific biological treatment strategies.
For professionals already working with PRP or other regenerative technologies, EXOMAS EXO offers an opportunity to evaluate a more advanced autologous concept.
Krios Biotech B.V. is the distributor of D-MED regenerative medicine technologies in the Netherlands and Belgium.
We support healthcare professionals with:
product information,
technical documentation,
scientific background,
and personalised guidance.
Our portfolio includes:
D-MED PRP systems
D-MED EXOMAS EXO
NUMATRIX Micro-Graft
CELLANOVA Elite SVF
LIPANOVA
BMAC systems
Suggested Visual 4:
A small product portfolio strip or icon row showing PRP, EXOMAS, NUMATRIX, CELLANOVA, and LIPANOVA.
Autologous extracellular vesicle-rich plasma preparation is an exciting and developing area of regenerative medicine.
If you are interested in learning more about D-MED EXOMAS EXO, Krios Biotech would be pleased to support you with further product information and technical documentation.